Infectious Disease

PUBLISHER: Coherent Market Insights | PRODUCT CODE: 1304400

PUBLISHER: Coherent Market Insights | PRODUCT CODE: 1304400

Anti-malarial Drugs Market, By Drug Class, By Route of Administration, By Distribution Channel, and By Region - Size, Share, Outlook, and Opportunity Analysis, 2023 - 2030

PUBLISHED: June 19, 2023

PAGES: 162 Pages

DELIVERY TIME: 2-3 business days

ADD TO COMPARE

SELECT AN OPTION

Description

Plasmodium parasites, a protozoan parasite, are the cause of the widespread infectious disease malaria. A parasite enters the body through the bite of an infected female Anopheles mosquito, which then travels to the liver, where the parasite is produced. Human malaria are generally caused by five types of plasmodium parasites, including P. falciparum, P. malariae, P. ovale, P. vivax, and P.knowlesi. The most dangerous parasite species among these are P. falciparum and P. vivax, which are also the ones responsible for the majority of malaria deaths. Antimalarial drugs are used for the treatment and prevention of malaria infection. Most antimalarial drugs target the erythrocytic stage of malaria infection, which is the phase of infection that causes symptomatic illness. Early diagnosis and efficient treatment are crucial measures to control malaria. Different types of drugs such as quinine, chloroquine, mefloquine, proguanil, primaquine, and others are used in the treatment of malaria. Moreover, some combination drugs such as Pyrimethamine & sulfadoxine, Artemether & lumefantrine, and others are also prescribed for treating the disease.

Market Dynamics

The ongoing research and development for malarial treatment is expected to fuel growth of the market in the forecast period. Various drugs are undergoing the clinical trial for the malarial treatment, which is also expected to drive the market during the forecast period. Moreover, various pharmaceutical companies are actively participating in research and development activities, in order to develop novel drug entity for treatment of malaria. For instance, in November 2022, Novartis AG, a multinational pharmaceutical corporation and Medicines for Malaria Venture (MMV), a product development partnership in the field of antimalarial drug research and development announced decision to move to Phase 3 study for novel non-artemisinin combination to treat uncomplicated malaria. This novel combination also contains an optimized formulation of lumefantrine, which allows it to be given once daily versus the usual twice-daily administration. As the world faces emerging resistance to current malaria treatments, new medicines are needed to continue the fight toward elimination.

Key features of the study:

This report provides in-depth analysis of the global anti-malarial drugs market, and provides market size (US$ Million) and Compound Annual Growth Rate (CAGR%) for the forecast period (2023-2030), considering 2022 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global anti-malarial drugs market based on the following parameters-company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study are Ipca Laboratories Ltd., Zydus Group, Merck KGaA, Pfizer Inc., GSK plc., Cipla Inc., Sun Pharmaceutical Industries Ltd., Novartis AG, Alvizia Health Care, Bayer AG, and F. Hoffmann-La Roche Ltd.
Insights from this report will allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
Global anti-malarial drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global anti-malarial drugs market

Detailed Segmentation:

Global Anti-malarial Drugs Market, By Drug Class:
- Aminoquinolines
- Quinoline-methanol (4-quinolinemethanols)
- Cinchona Alkaloids
- Biguanides
- Sulfonamides and sulfones
- Others
Global Anti-malarial Drugs Market By Route of Administration:
- Oral
- Injectable
Global Anti-malarial Drugs Market By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Global Anti-malarial Drugs Market, By Region:
- North America
  - By Country:
- U.S.
- Canada
- Latin America
  - By Country:
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
  - By Country:
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
  - By Country
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
  - By Country:
- GCC
- Israel
- Rest of Middle East
- Africa
  - By Country/Region:
- South Africa
- Central Africa
- North Africa
Company Profiles
- Ipca Laboratories Ltd.*
  - Company Highlights
  - Products Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Zydus Group
- Merck KGaA
- Pfizer Inc.
- GSK plc.
- Cipla Inc.
- Sun Pharmaceutical Industries Ltd.
- Novartis AG
- Alvizia Health Care
- Bayer AG
- F.Hoffmann-La Roche Ltd

"*" marked represents similar segmentation in other categories in the respective section

Product Code: CMI3726

1. Research Objective and Assumption

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snippet, By Drug Class
- Market Snippet, By Route of Administration
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
- Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Market Opportunities
Impact Analysis
Recent Product Launches
Epidemiology
Merger, Acquisition, and Collaborations
Regulatory Scenario
Key Developments
PEST Analysis

4. Global Anti-malarial Drugs Market- Impact of Coronavirus (Covid-19) Pandemic

Economic Impact
COVID-19 Epidemiology
Impact on Supply and Demand

5. Global Anti-malarial Drugs Market, By Drug Class, 2018-2030 (US$ Mn)

Introduction
- Market Share Analysis, 2023 and 2030(%)
- Y-o-Y Growth Analysis, 2018-2030
- Segment Trends
Aminoquinolines
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
Quinoline-methanol (4-quinolinemethanols)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
Cinchona Alkaloids
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
Biguanides
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
Sulfonamides and sulfones
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)

6. Global Anti-malarial Drugs Market, By Route of Administration, 2018-2030 (US$ Mn)

Introduction
- Market Share Analysis, 2023 and 2030(%)
- Y-o-Y Growth Analysis, 2018-2030
- Segment Trends
Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
Injectable
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)

7. Global Anti-malarial Drugs Market, By Distribution Channel, 2018-2030 (US$ Mn)

Introduction
- Market Share Analysis, 2023 and 2030(%)
- Y-o-Y Growth Analysis, 2018 - 2030
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size, Volume and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
Retail Pharmacies
- Introduction
- Market Size, Volume and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
Online Pharmacies
- Introduction
- Market Size, Volume and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)

8. Global Anti-malarial Drugs Market, By Region, 2018-2030, (US$ Mn)

Introduction
- Market Share Analysis, By Region, 2023 and 2030(%)
- Y-o-Y Growth Analysis, For Regions, 2018-2030
North America
- Market Size and Forecast, By Drug Class, 2018-2030, (US$ Mn)
- Market Size and Forecast, By Route of Administration, 2018-2030, (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2018-2030, (US$ Mn)
- Market Size and Forecast, By Country, 2018-2030, (US$ Mn)
U.S.
Canada
Latin America
- Market Size and Forecast, By Drug Class, 2018-2030, (US$ Mn)
- Market Size and Forecast, By Route of Administration, 2018-2030, (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2018-2030, (US$ Mn)
- Market Size and Forecast, By Country, 2018-2030, (US$ Mn)
Brazil
Mexico
Argentina
Rest of Latin America
Europe
- Market Size and Forecast, By Drug Class, 2018-2030, (US$ Mn)
- Market Size and Forecast, By Route of Administration, 2018-2030, (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2018-2030, (US$ Mn)
- Market Size and Forecast, By Country, 2018-2030, (US$ Mn)
Germany
U.K.
France
Italy
Spain
Russia
Rest of Europe
Asia Pacific
- Market Size and Forecast, By Drug Class, 2018-2030, (US$ Mn)
- Market Size and Forecast, By Route of Administration, 2018-2030, (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2018-2030, (US$ Mn)
- Market Size and Forecast, By Country, 2018-2030, (US$ Mn)
China
India
Japan
Australia
South Korea
ASEAN
Rest of APAC
Middle East
- Market Size and Forecast, By Drug Class, 2018-2030, (US$ Mn)
- Market Size and Forecast, By Route of Administration, 2018-2030, (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2018-2030, (US$ Mn)
- Market Size and Forecast, By Country, 2018-2030, (US$ Mn)
GCC
Israel
Rest of Middle East
Africa
- Market Size and Forecast, By Drug Class, 2018-2030, (US$ Mn)
- Market Size and Forecast, By Route of Administration, 2018-2030, (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2018-2030, (US$ Mn)
- Market Size and Forecast, By Country, 2018-2030, (US$ Mn)
South Africa
Central Africa
North Africa

9. Competitive Landscape

Company Profiles
- Ipca Laboratories Ltd.
Company Overview
Product Portfolio
Key Developments
Financial Performance
Strategies
- Zydus Group
Company Overview
Product Portfolio
Key Developments
Financial Performance
Strategies
- Merck KGaA
Company Overview
Product Portfolio
Key Developments
Financial Performance
Strategies
- Pfizer Inc.
Company Overview
Product Portfolio
Key Developments
Financial Performance
Strategies
- GSK plc.
Company Overview
Product Portfolio
Key Developments
Financial Performance
Strategies
- Cipla Inc.
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Strategies
- Sun Pharmaceutical Industries Ltd.
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Strategies
- Novartis AG
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Strategies
- Alvizia Health Care
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Strategies
- Bayer AG
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Strategies
- F. Hoffmann-La Roche Ltd
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Strategies

10. Section

References
Research Methodology
About us and Sales Contact

Have a question?

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Christine Sirois

Manager - Americas

+1-860-674-8796

SEE OUR FAQ